drugset / Trial / NCT02254551
Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the study is to determine whether the combination of LDE225 (sonidegib) plus bortezomib is safe and effective in the treatment of relapsed or relapsed/refractory multiple myeloma.
Timeline
- Start
- 2015-01
- Primary completion
- 2015-10
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sonidegib | Small molecule | 400 mg | Oral |
| Subject | Sonidegib | Small molecule | 800 mg | Oral |
| Background | Bortezomib | Small molecule | 1.3 mg/m2 | Subcutaneous |